Cure TV

Get a sneak peek at what’s inside our Winter 2020 issue of Heal Magazine.

Here are the top five CURE® stories for February 2020.

Utilizing the data of the CheckMate 9ER trial, researchers believe that combination therapies in the treatment of patients with renal cell carcinoma are the future of the landscape.

Here’s a look at what’s inside our 2020 Winter issue.

Treatments for renal cell carcinoma are showing effectiveness in the short term, but with the help of new trials, researchers are looking to expand their impact for long term treatment.

The landscape for patients with renal cell carcinoma could potentially change as the use of immune checkpoint inhibition shows promise for these patients.

A recent study looking at data from three clinical trials involving Nerlynx shows promise for the future of treating patients with HER-2 positive breast cancer who develop CNS metastases.

The results of a phase 2 study looking at Padcev and Keytruda combination therapy for patients with metastatic urothelial cancer shows promise with a 73% response that did not differ for a patient’s PDL1 status.

The incidence of colorectal and gastric cancers has risen for younger patients, and many of them share ethnic and socioeconomic disparities as well.

A subset of patients with metastatic pancreatic cancer and an inherited BRCA mutation rapidly progressed during a clinical trial of Lynparza.

A circulating cell-free DNA test for patients with gastrointestinal cancers has a 90% accuracy rate to detect patients’ cancers and could provide a standard test in the future, according to new study findings.

The combination treatment of Tecentriq (atezolizumab) and Avastain (bevacizumab) improved patient-reported outcomes and quality of life in a recent phase 3 study.

The cancer landscape has changed for patients with the introduction of targeted therapies, and a combination targeted therapy for some patients with colorectal cancer shows new promise.

The expert who created an assessment tool to help patients with myeloproliferative neoplasms explain their symptoms to their care ream shares how the idea came to fruition.

Kurt Schroeder, a research nurse, pushes for a patient-first mentality, especially as they participate in a clinical trial.

Ann McMullin fought for her son to be properly diagnosed and is advocating for more education among medical professionals of rare diseases like her son’s essential thrombocythemia.

As a guest speaker at the 2019 MPN Heroes ® Recognition Ceremony, Dr. David C. Fajenbaum had the chance to discuss how translational research is a vital part of getting the right treatment to patients with cancer.

Because they have been found to be effective in the treatment of many types of cancer, including melanoma, immunotherapy drugs like anti-PD-1 agents and anti-CTLA4 therapies should not be discounted because of their toxicities.

Emergency room visits are costly and take a lot of time patients with cancer don’t have, which is why the creation of a 24-hour clinic to address cancer related symptoms and treatment side effects could prove vital for patients.

Cannon McMullin was diagnosed with essential thrombocythemia at 8 years old and has remained positive through years of treatment by focusing on the things he likes to do.

For Natalie Catalano, caregiving for her daughter with essential thrombocythemia included not only being a rock of support, but also being a vocal advocate for her daughter’s care team to make the right diagnosis.

Madeleine Henriquez noticed that the mental health care of patients with MPN was being overlooked and took action in a way that has changed her community for the better.

Typically, the longer a patient with cancer is exposed to a drug the more side effects they experience, but in the case of Imbruvica, the opposite appears to be true for patients with MCL.

Patients with rare blood cancers are not all the same, and this understanding has helped Dr. Irum Khan become an advocate for people with these conditions — and an MPN Hero.

Researchers are exploring ways to limit the duration of treatment in chronic lymphocytic leukemia in order to reduce costs.

Young women and women of color with breast cancer, as well as those with metastatic disease, had the chance to experience SABCS 2019 and advocate for representation of their patient groups in ongoing clinical trials.

The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.